Skip to main content
Top
Literature
1.
go back to reference Richards A, Hagelstein S, Patel G, Ivins N, Sweetland H, Harding K (2011) Early use of negative pressure therapy in combination with silver dressings in a difficult breast abscess. Int Wound J 8:608–611PubMedCrossRef Richards A, Hagelstein S, Patel G, Ivins N, Sweetland H, Harding K (2011) Early use of negative pressure therapy in combination with silver dressings in a difficult breast abscess. Int Wound J 8:608–611PubMedCrossRef
2.
go back to reference Meislin HW, Lerner SA, Graves MH, McGehee MD, Kocka FE, Morello JA, Rosen P (1977) Cutaneous abscesses. Anaerobic and aerobic bacteriology and outpatient management. Ann Intern Med 87:145–149PubMedCrossRef Meislin HW, Lerner SA, Graves MH, McGehee MD, Kocka FE, Morello JA, Rosen P (1977) Cutaneous abscesses. Anaerobic and aerobic bacteriology and outpatient management. Ann Intern Med 87:145–149PubMedCrossRef
3.
go back to reference Semprini G, Cattin F, Vaienti L, Brizzolari M, Cedolini C, Parodi PC (2013) Oncoplastic surgery and cancer relapses: cosmetic and oncological results in 489 patients. Breast 22(5):946–951PubMedCrossRef Semprini G, Cattin F, Vaienti L, Brizzolari M, Cedolini C, Parodi PC (2013) Oncoplastic surgery and cancer relapses: cosmetic and oncological results in 489 patients. Breast 22(5):946–951PubMedCrossRef
Metadata
Title
The therapy with negative pressure as a valid device to treat chronic breast infections
Authors
Tommaso Fogacci
Federico Cattin
Domenico Samorani
Publication date
01-01-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3650-6

Other articles of this Issue 1/2016

Breast Cancer Research and Treatment 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine